- Adjusted operating profit for BioMerieux in the fiscal year was EU610 million, a decrease of 8.1% year-on-year (y/y).
- The net income stood at EU358 million, a 21% decrease y/y.
- Dividend per share was EU0.85, higher than the estimated EU0.76.
- Sales reached EU3.68 billion, a 2.4% increase y/y and slightly above the estimated EU3.67 billion.
- The company forecasts an organic sales growth of between 6% and 8% for the next year.
- Operating income before non-recurring items is expected to grow by at least 10% at constant exchange rates in 2024.
- Operating margin is expected to improve by at least 50 basis points at constant exchange rate in 2024.
- A negative foreign exchange impact of around -€50 million is anticipated in 2024 compared to 2023.
- Sales of non-respiratory BIOFIRE panels are projected to continue growing rapidly in 2024, leveraging the large installed base of BIOFIRE instruments.
- BIOFIRE SPOTFIRE sales in 2024 are projected to reach approximately €80m.
- Microbiology sales are expected to grow by around 8% in 2024.
- Sales of BIOFIRE respiratory panels are expected to slow down slightly in 2024, assuming a medium flu season in the fourth quarter.
- The company received 11 buy ratings, 3 hold ratings, and no sell ratings.
A look at BioMerieux Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
BioMerieux, a company that focuses on in vitro diagnostics for medical and industrial use, has a positive long-term outlook according to Smartkarma’s Smart Scores. The company received a score of 2 for Value, indicating that it may be undervalued and have potential for growth. Additionally, BioMerieux received a score of 2 for Dividend, meaning that it may offer stable dividends for investors.
Smartkarma also gave BioMerieux a score of 3 for Growth, suggesting that the company has potential for future growth and expansion. Furthermore, with a score of 4 for both Resilience and Momentum, BioMerieux is considered to be a strong and stable company with positive momentum in the market.
Overall, BioMerieux‘s strong scores in various categories indicate a positive long-term outlook for the company. With its focus on in vitro diagnostics for both medical and industrial purposes, BioMerieux is well-positioned for potential growth and success in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
